TITLE:
Feasibility of Concurrent Radiotherapy and Paclitaxel-Based Chemotherapy after Conservative Surgery for Breast Cancer
AUTHORS:
Hamza Abbas, Alia M. Attia, Ahmed A. S. Salem, Gamal Amira, Adel Gabr, Reham El Morshedy, Mohamed Hamdy
KEYWORDS:
Breast Cancer, BCS, Concurrent Radiotherapy and Paclitaxel
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.11,
November
30,
2017
ABSTRACT: Purpose: Our prospective phase II trial aims to show the feasibility of adjuvant paclitaxel-based concurrent
chemoradiotherapy (CCRT) following doxorubicin and cyclophosphamide (AC) to get
the survival benefit of taxanes addition and avoid delay of radiotherapy. Patients
and Methods: A total of 63 patients
with pT1-2,
and pN1-3, M0 breast cancer underwent conservative surgery followed by adjuvant
4 cycles AC followed by 4 cycles Paclitaxel 175 mg/m2 every 3 weeks. Adjuvant radiotherapy started during the
first and second cycle of paclitaxel (CCRT). Toxicities evaluated at the base time, weekly during
radiation therapy and every 3 months for 24 months for skin, pulmonary,
cardiac, lymphedema, subcutaneous fibrosis and cosmoses. Survival reported at
2-year median
follow-up. Results: At median follow up time of 24 months (6 - 30), we did not report any toxicity postpone or stop
treatment and only two patients had grade III acute dermatitis. Fifty-two patients (82.5%) had
satisfactory cosmoses and none of
the patients
developed local recurrence. Conclusion: Three-weekly paclitaxel during
radiotherapy is considered safe without significant complications and
acceptable cosmoses with excellent local control and could be considered to
avoid radiotherapy delay.